1. Market Research
  2. > Muscle Wasting Disorders - Pipeline Review, H2 2013

Muscle Wasting Disorders - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 83 pages

Muscle Wasting Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Muscle Wasting Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Muscle Wasting Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscle Wasting Disorders. Muscle Wasting Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Muscle Wasting Disorders.
- A review of the Muscle Wasting Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Muscle Wasting Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Muscle Wasting Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Muscle Wasting Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Muscle Wasting Disorders - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Muscle Wasting Disorders Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Muscle Wasting Disorders 9
Muscle Wasting Disorders Therapeutics under Development by Companies 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Muscle Wasting Disorders Therapeutics - Products under Development by Companies 17
Companies Involved in Muscle Wasting Disorders Therapeutics Development 18
Eli Lilly and Company 18
GlaxoSmithKline plc 19
Plexxikon Inc. 20
BioLineRx, Ltd. 21
Novartis AG 22
Aphios Corporation 23
GTx, Inc. 24
Rigel Pharmaceuticals, Inc. 25
Ligand Pharmaceuticals Incorporated 26
Calzada Limited 27
Palatin Technologies, Inc. 28
Cytokinetics, Inc 29
AnaptysBio, Inc. 30
Fate Therapeutics, Inc. 31
NGM Biopharmaceuticals, Inc. 32
Progenra, Inc. 33
Rhythm Pharmaceuticals 34
Muscle Wasting Disorders - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
enobosarm - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
RM-131 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
BL-5040 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
dronabinol - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
LGD-4033 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Atropy Inhibitor - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
LY-2495655 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
CK-2066260 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
FT-301 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
BYM-338 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Drug For Cachexia - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
ANA-012 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
CK-2127107 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
PLX-4720 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
GSK-2849466 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Drug Targeting USP19 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
P-013222 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Skeletal Muscle Program - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
FB-704 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Muscle Wasting Disorders Therapeutics - Drug Profile Updates 64
Muscle Wasting Disorders Therapeutics - Discontinued Products 72
Muscle Wasting Disorders Therapeutics - Dormant Products 73
Muscle Wasting Disorders - Product Development Milestones 74
Featured News and Press Releases 74
Jun 28, 2013: GTx Presents On Enobosarm For Prevention And Treatment Of Muscle Wasting In Cancer Patients At 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer 74
May 30, 2013: GTx To Present On Enobosarm For Muscle Wasting In Non-Small Cell Lung Cancer At 2013 ASCO Annual Meeting 75
Apr 15, 2013: GTx's Phase III Clinical Studies Of Enobosarm To Continue As Planned Following Planned Safety Review 76
Apr 01, 2013: Cytokinetics Initiates Phase I Clinical Trial Of CK-2127107 76
Mar 14, 2013: GTx Announces Publication Of Enobosarm Phase II Trial Results In The Lancet Oncology 77
Jan 21, 2013: Theratechnologies Announces FDA Approval Of Alternative Storage Conditions For Egrifta 79
Jan 08, 2013: GTx's Enobosarm Receives FDA Fast Track Designation For Prevention And Treatment Of Muscle Wasting In Patients With Non-small Cell Lung Cancer 79
Jan 03, 2013: Alize Pharma Launches PREMAG Research Program 79
Dec 17, 2012: GTx Attains Enrollment Goal For Its Enobosarm POWER 1 And POWER 2 Phase III Clinical Studies 81
Oct 29, 2012: GTx To Continue Phase III Clinical Development Of Enobosarm For Muscle Wasting In Lung Cancer Patients Following Planned Safety Review 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83

List of Tables

Number of Products Under Development for Muscle Wasting Disorders, H2 2013 9
Products under Development for Muscle Wasting Disorders - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Comparative Analysis by Late Stage Development, H2 2013 13
Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Clinical Stage Development, H2 2013 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 16
Products under Development by Companies, H2 2013 17
Eli Lilly and Company, H2 2013 18
GlaxoSmithKline plc, H2 2013 19
Plexxikon Inc., H2 2013 20
BioLineRx, Ltd., H2 2013 21
Novartis AG, H2 2013 22
Aphios Corporation, H2 2013 23
GTx, Inc., H2 2013 24
Rigel Pharmaceuticals, Inc., H2 2013 25
Ligand Pharmaceuticals Incorporated, H2 2013 26
Calzada Limited, H2 2013 27
Palatin Technologies, Inc., H2 2013 28
Cytokinetics, Inc, H2 2013 29
AnaptysBio, Inc., H2 2013 30
Fate Therapeutics, Inc., H2 2013 31
NGM Biopharmaceuticals, Inc., H2 2013 32
Progenra, Inc., H2 2013 33
Rhythm Pharmaceuticals, H2 2013 34
Assessment by Monotherapy Products, H2 2013 35
Assessment by Stage and Route of Administration, H2 2013 37
Assessment by Stage and Molecule Type, H2 2013 39
Muscle Wasting Disorders Therapeutics - Drug Profile Updates 64
Muscle Wasting Disorders Therapeutics - Discontinued Products 72
Muscle Wasting Disorders Therapeutics - Dormant Products 73

List of Figures

Number of Products under Development for Muscle Wasting Disorders, H2 2013 9
Products under Development for Muscle Wasting Disorders - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Late Stage Products, H2 2013 13
Mid Clinical Stage Products, H2 2013 14
Early Clinical Stage Products, H2 2013 15
Discovery and Pre-Clinical Stage Products, H2 2013 16
Assessment by Monotherapy Products, H2 2013 35
Assessment by Route of Administration, H2 2013 36
Assessment by Stage and Route of Administration, H2 2013 37
Assessment by Molecule Type, H2 2013 38
Assessment by Stage and Molecule Type, H2 2013 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.